bluebird bio
NEWS
A look at some of the exciting data clinicians and investors got to feast on from ASH.
Celgene and bluebird bio released updated data from an ongoing Phase I clinical trial of bb2121 at the ASH Annual Meeting.
These great biotech stocks to buy for the holidays come in all sizes -- small-cap, mid-cap, and large-cap.
The company has snapped up manufacturing space in North Carolina’s Research Triangle Park to internally produce lentiviral vector for the company’s gene and cell therapies.
The drug developed by Alkermes took a lot of flack but proved effective in a recent study.
At 14.1%, healthcare is the third largest weighted sector in the S&P 500 index, and with 76 million baby boomers getting older and living longer, owning healthcare stocks in your portfolio makes sense.
Bluebird is making forays into the CAR-T immuno-oncology market, although it has yet to bring a product to market.
Immuno-oncology and gene therapy has been a hot field for the last few years, and the approval of the first CAR-T therapies has only set the kindling ablaze.
On Oct. 13, the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee unanimously recommended Spark’s Luxturna in a vote of 16 to 0.
JOBS